Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ulcerative colitis in northern Portugal and Galicia in Spain.
Barreiro-de Acosta M, Magro F, Carpio D, Lago P, Echarri A, Cotter J, Pereira S, Gonçalves R, Lorenzo A, Carvalho L, Castro J, Barros L, Dias JA, Rodrigues S, Portela F, Dias C, da Costa-Pereira A; GEDII; EIGA. Barreiro-de Acosta M, et al. Among authors: portela f. Inflamm Bowel Dis. 2010 Jul;16(7):1227-38. doi: 10.1002/ibd.21170. Inflamm Bowel Dis. 2010. PMID: 19924807 Free article.
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Rubin DT, et al. Lancet. 2025 Jan 4;405(10472):33-49. doi: 10.1016/S0140-6736(24)01927-5. Epub 2024 Dec 17. Lancet. 2025. PMID: 39706209 Clinical Trial.
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr; INSPIRE and COMMAND Study Group. Louis E, et al. JAMA. 2024 Sep 17;332(11):881-897. doi: 10.1001/jama.2024.12414. JAMA. 2024. PMID: 39037800 Clinical Trial.
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Sands BE, et al. N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. N Engl J Med. 2019. PMID: 31553834 Clinical Trial.
High-intensity interval training improves hepatic redox status via Nrf2 downstream pathways and reduced CYP2E1 expression in female rats with cisplatin-induced hepatotoxicity.
Portela FS, Malheiro LFL, Oliveira CA, Mercês ÉAB, De Benedictis LM, De Benedictis JM, Fernandes AJV, Silva BS, Ávila JS, Correia TML, Oliveira MV, Silva Oliveira PD, Magalhães ACM, Soares TJ, Melo FF, Amaral LSB. Portela FS, et al. Food Chem Toxicol. 2024 Dec 31;196:115234. doi: 10.1016/j.fct.2024.115234. Online ahead of print. Food Chem Toxicol. 2024. PMID: 39746600
Serum Neutrophil Biomarkers to Predict Crohn's Disease Progression and Infliximab Treatment Outcomes.
Magalhaes D, Santiago M, Patita M, Arroja B, Lago P, Rosa I, Sousa HT, Ministro P, Mocanu I, Vieira A, Castela J, Moleiro J, Roseira J, Eugenia C, Sousa P, Portela F, Correia L, Dias S, Afonso J, Danese S, Peyrin-Biroulet L, Dias CC, Magro F; GEDII. Magalhaes D, et al. Among authors: portela f. United European Gastroenterol J. 2024 Dec 8. doi: 10.1002/ueg2.12712. Online ahead of print. United European Gastroenterol J. 2024. PMID: 39648597 Free article.
Plasma calprotectin as a biomarker of inflammatory activity in ulcerative colitis.
Temido MJ, Peixinho M, Cunha R, Silva A, Lopes S, Mendes S, Ferreira AM, Ferreira M, Figueiredo P, Portela F. Temido MJ, et al. Among authors: portela f. Med Clin (Barc). 2024 Nov 15:S0025-7753(24)00597-9. doi: 10.1016/j.medcli.2024.09.009. Online ahead of print. Med Clin (Barc). 2024. PMID: 39550244 English, Spanish.
200 results